Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Indaptus Therapeutics Inc’s stock clocked out at $3.59, up 2.57% from its previous closing price of $3.5. In other words, the price has increased by $2.57 from its previous closing price. On the day, 0.92 million shares were traded. INDP stock price reached its highest trading level at $4.5 during the session, while it also had its lowest trading level at $3.4.
Ratios:
To gain a deeper understanding of INDP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.75 and its Current Ratio is at 0.75.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INDP now has a Market Capitalization of 3972439 and an Enterprise Value of 4351614.
Stock Price History:
The Beta on a monthly basis for INDP is 1.26, which has changed by -0.88947046 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, INDP has reached a high of $58.24, while it has fallen to a 52-week low of $2.22. The 50-Day Moving Average of the stock is -36.73%, while the 200-Day Moving Average is calculated to be -75.05%.
Shares Statistics:
It appears that INDP traded 368.22K shares on average per day over the past three months and 1914250 shares per day over the past ten days. A total of 1.11M shares are outstanding, with a floating share count of 1.00M. Insiders hold about 9.46% of the company’s shares, while institutions hold 4.58% stake in the company. Shares short for INDP as of 1757894400 were 547301 with a Short Ratio of 1.49, compared to 1755216000 on 18667. Therefore, it implies a Short% of Shares Outstanding of 547301 and a Short% of Float of 56.8.
Earnings Estimates
The dynamic stock of Indaptus Therapeutics Inc (INDP) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$4.32, with high estimates of -$4.32 and low estimates of -$4.32.
Analysts are recommending an EPS of between -$26.58 and -$26.58 for the fiscal current year, implying an average EPS of -$26.58. EPS for the following year is -$13.9, with 1.0 analysts recommending between -$13.9 and -$13.9.
